



Acadia Pharmaceuticals Inc. is providing this letter in response to your unsolicited request for medical information. It is for scientific exchange and individual educational purposes only, and should not be copied or distributed. Information included in this letter may not be consistent with the US FDA-approved Prescribing Information for DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide) or may be related to unapproved uses. This letter is not intended to advocate any unapproved or approved use, indication, dosage, or other treatment-related decision. Acadia strives to provide current, accurate, and fair-balanced information in compliance with current industry information dissemination guidelines.

For further information regarding Indication and Important Safety Information for DAYBUE and DAYBUE STIX, please click here: [Prescribing Information](#).

DAYBUE® (trofinetide): Results from the Phase 3 LAVENDER™ Study

This letter is provided in response to your specific request for information regarding the results from the Phase 3 clinical trial of trofinetide in Rett syndrome (RTT).

Summary


- The 12-week [Phase 3 LAVENDER study](#) evaluated the efficacy and safety of trofinetide in 187 female participants (5–20 years old) with RTT.¹
- A statistically significant improvement over placebo was demonstrated for both [co-primary endpoints](#).¹ On the Rett Syndrome Behaviour Questionnaire (RSBQ) total score, the least squares mean (LSM) change from baseline to Week 12 was -4.9 for trofinetide (N=91) vs. -1.7 for placebo (N=93) (LSM treatment difference -3.2 [95% CI -5.7, -0.6]; p=0.018; effect size=0.37). The LSM Clinical Global Impression-Improvement (CGI-I) score at Week 12 was 3.5 for trofinetide vs. 3.8 for placebo (LSM treatment difference -0.3 [95% CI -0.5, -0.1]; p=0.003; effect size=0.47).^{1,2}
- [Treatment emergent adverse events \(TEAEs\)](#) were reported in 92.5% of participants in the trofinetide arm (N=93) and 54.3% in the placebo arm (N=94), with TEAEs leading to discontinuation in 17.2% and 2.1%, respectively, and serious TEAEs in 3.2% of each group.¹
- The most [common TEAEs](#) were diarrhea (80.6% with trofinetide vs. 19.1% with placebo) and vomiting (26.9% with trofinetide vs. 9.6% with placebo). Most TEAEs of diarrhea and vomiting in the trofinetide group (97.3% and 96.0%, respectively) were characterized as mild-to-moderate.¹

Phase 3 LAVENDER Study (ACP-2566-003)

This was a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study in 187 female participants (5–20 years old) with a diagnosis of typical RTT according to the Rett Syndrome Diagnostic Criteria and a documented disease-causing mutation in the *MECP2* gene (**Figure 1**).^{1,2}

Participants received trofinetide 30–60 mL BID or placebo, based on the participant's weight at baseline (**Table 1**). The primary objective of this study was to investigate the efficacy of treatment with oral trofinetide versus placebo in girls and women with RTT. Co-primary efficacy endpoints measured symptoms using the caregiver-assessed RSBQ total score (change from baseline to Week 12) and the clinician-assessed CGI-I (score at Week 12). The key secondary endpoint was change from baseline to Week 12 in the CSBS-DP-IT Social.^{1,3}

Figure 1. LAVENDER Study Design^{1,3}



*Dose based on participant's body weight at baseline.

[†]The LAVENDER follow-up visit does not take place if the participant rolls over into the open-label extension study.

Abbreviations: BID=twice a day; CGI-I=Clinical Global Impression-Improvement; CSBS-DP-IT Social=Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist – Social Composite Score; PO=oral; RSBQ=Rett Syndrome Behaviour Questionnaire.

Table 1. Dosing Schedule Based on Weight at Baseline¹

Weight	Dose	Total daily dose
12–20 kg	30 mL BID	60 mL
>20–35 kg	40 mL BID	80 mL
>35–50 kg	50 mL BID	100 mL
>50 kg	60 mL BID	120 mL

Abbreviation: BID=twice daily.

Selected inclusion and exclusion criteria are shown in **Table 2**.

Table 2. Selected Inclusion and Exclusion Criteria^{4,5}

Selected inclusion criteria
• Female subjects 5 to 20 years of age, inclusive, at screening • Body weight ≥12 kg at screening • Can swallow the study medication provided as a liquid solution or can take it by gastrostomy tube • Classic/typical RTT • Documented disease-causing mutation in the <i>MECP2</i> gene • At least 6 months post regression at screening • Severity rating of 10–36, inclusive, on the RTT Clinical Severity Scale at screening • CGI-S score of ≥4 • Stable pattern of seizures, or had no seizures, within 8 weeks of screening
Selected exclusion criteria
• Had been treated with insulin within 12 weeks of baseline • Current clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory or gastrointestinal disease (such as celiac disease or inflammatory bowel disease) or major surgery planned during the study • A history of, or current, cerebrovascular disease or brain trauma • Significant, uncorrected visual or uncorrected hearing impairment • A history of, or current, malignancy • A known history or symptoms of long QT syndrome

Abbreviations: CGI-S=Clinical Global Impression-Severity; MECP2=Methyl-CpG Binding Protein 2; RTT=Rett syndrome.

Baseline Characteristics

Demographic and baseline disease characteristics were well balanced between the treatment groups.¹ In the Randomized Analysis Set (all randomized participants),³ the mean (standard deviation [SD]) age of participants was 10.9 (4.62) years overall, with a mean (SD) baseline CGI-S score of 4.9 (0.76) (**Table 3**). In the respective trofinetide and placebo groups, 40.9% and 41.5% of participants were administered study medication via gastrostomy tube.¹

Table 3. Baseline Demographics and Disease Characteristics – Randomized Analysis Set*¹

	Placebo (N=94)	Trofinetide (N=93)	Total (N=187)
Age, years (mean ± SD)	10.9 ± 4.57	11.0 ± 4.69	10.9 ± 4.62
Age categories, n (%)			
5 to 10 Years	52 (55.3)	49 (52.7)	101 (54.0)
11 to 15 Years	24 (25.5)	25 (26.9)	49 (26.2)
16 to 20 Years	18 (19.1)	19 (20.4)	37 (19.8)
Primary race, n (%)			
White	90 (95.7)	82 (88.2)	172 (92.0)
Black or African American	1 (1.1)	1 (1.1)	2 (1.1)
Asian	1 (1.1)	5 (5.4)	6 (3.2)
Native Hawaiian or other Pacific Islander	0	1 (1.1)	1 (0.5)
Other	2 (2.1)	4 (4.3)	6 (3.2)
RTT-CSS score at screening (mean ± SD)	24.2 ± 6.68	24.1 ± 6.40	24.1 ± 6.53
RSBQ total score (mean ± SD)	44.4 ± 12.13	43.8 ± 11.42	44.1 ± 11.76
RSBQ severity, n (%)			
<35	25 (26.6)	23 (24.7)	48 (25.7)
≥35	69 (73.4)	70 (75.3)	139 (74.3)
Baseline CGI-S score (mean ± SD)	4.9 ± 0.76	4.9 ± 0.77	4.9 ± 0.76
Baseline CGI-S category, n (%)			
1 (Normal) to 3 (Mildly ill)	0	0	0
4 (Moderately ill)	33 (35.1)	32 (34.4)	65 (34.8)
5 (Markedly ill)	42 (44.7)	38 (40.9)	80 (42.8)
6 (Severely ill)	18 (19.1)	23 (24.7)	41 (21.9)
7 (Among the most extremely ill patients)	1 (1.1)	0	1 (0.5)
CSBS-DP-IT Social (mean ± SD)	8.9 ± 3.23	8.7 ± 3.32	8.8 ± 3.27

*No significant differences ($p \leq 0.05$) were detected between the study groups.

Abbreviations: CGI-S=Clinical Global Impression-Severity; CSBS-DP-IT Social = Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist – Social Composite Score; CSS=clinical severity scale; RSBQ = Rett Syndrome Behaviour Questionnaire; RTT=Rett syndrome; SD=standard deviation.

MECP2 mutations were categorized as mild, moderate, or severe based on categories used to report findings from the Rett Syndrome Natural History Study (**Table 4**).^{1,6} In the Safety Analysis Set (all randomized participants who received ≥1 dose of study medication), 75.3% of participants in the trofinetide group (N=93) had a history of constipation, compared with 78.7% in the placebo group (N=94) (**Table 4**).¹

Table 4. MECP2 Gene Mutation Severity and Selected Medical History – Safety Analysis Set*¹

	Placebo (N=94)	Trofinetide (N=93)
MECP2 gene mutation severity, n (%)		
Mild	37 (39.4)	30 (32.3)
Moderate	8 (8.5)	13 (14.0)
Severe	46 (48.9)	46 (49.5)
Unknown	3 (3.2)	4 (4.3)
Selected medical history, n (%)		
Constipation	74 (78.7)	70 (75.3)
Seizure	47 (50.0)	40 (43.0)
Epilepsy	16 (17.0)	20 (21.5)
Focal dyscognitive seizures	1 (1.1)	2 (2.2)
Partial seizures	1 (1.1)	2 (2.2)
Status epilepticus	2 (2.1)	1 (1.1)
Gastrostomy	34 (36.2)	37 (39.8)


*No significant differences ($p \leq 0.05$) were detected between the study groups.

Abbreviations: MECP2=Methyl-CpG Binding Protein 2; RTT=Rett syndrome.

Efficacy Results


In the Full Analysis Set (all randomized participants who received ≥ 1 dose of study medication and who have both a baseline value and ≥ 1 post-baseline value for the RSBQ total score or who have ≥ 1 post-baseline value for the CGI-I score), a statistically significant improvement over placebo was demonstrated for both co-primary endpoints.^{1,3} The mean (SE) change from baseline to Week 12 in the RSBQ total score was -5.1 (0.99) and -1.7 (0.98) in the trofinetide and placebo groups, respectively. Based on the MMRM analysis, the LSM change from baseline to Week 12 on the RSBQ was -4.9 vs. -1.7 for trofinetide and placebo, respectively (LSM treatment difference -3.2 [95% CI -5.7, -0.6]; $p=0.018$; effect size=0.37; **Figure 2**). The LSM CGI-I score at Week 12 was 3.5 vs. 3.8 for trofinetide and placebo, respectively (LSM treatment difference -0.3 [95% CI -0.5, -0.1]; $p=0.003$; effect size=0.47; **Figure 3** and **Figure 4**).^{1,2}

Figure 2. RSBQ Change from Baseline by Visit (LSM $\pm$ SE) (OC; MMRM) – Full Analysis Set¹




Abbreviations: LSM=least squares mean; MMRM=mixed model repeated measures; OC=observed cases; RSBQ=Rett Syndrome Behaviour Questionnaire; SE=standard error.

Figure 3. CGI-I Score by Visit (LSM $\pm$ SE) (OC; MMRM) – Full Analysis Set¹



Abbreviations: CGI-I=Clinical Global Impression-Improvement; LSM=least squares mean; MMRM=mixed model repeated measures; OC=observed cases; SE=standard error.


Figure 4. Distribution of CGI-I Scores for Patients Completing LAVENDER – Full Analysis Set²



Abbreviation: CGI-I=Clinical Global Impression-Improvement.

Trofinetide additionally demonstrated a statistically significant separation over placebo on the key secondary endpoint, the LSM change from baseline to Week 12 in CSBS-DP-IT Social. The score was -0.1 vs. -1.1 for trofinetide and placebo, respectively (LSM difference of 1.0 [95% CI 0.3 to 1.7]; $p=0.006$; effect size=0.43; **Figure 5**).¹ This secondary endpoint analysis should be interpreted with caution for the following reasons: the CSBS-DP-IT Social is intended to be a screening tool to identify potential communication issues in otherwise healthy infants/toddlers; this tool has not been validated for use in patients with Rett syndrome; and the 13-items that make the social composite score do not represent the full concept of social reciprocity.

Figure 5. CSBS-DP-IT Social Composite Score Change from Baseline by Visit (LSM $\pm$ SE) (OC; MMRM) – Full Analysis Set^{7,8}



Abbreviations: CSBS-DP-IT Social=Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist – Social Composite Score; LSM=least squares mean; MMRM=mixed model repeated measures; OC=observed cases; SE=standard error.

Safety Results

In the Safety Analysis Set, in the respective trofinetide and placebo groups, at least one TEAE was reported in 86 (92.5%) and 51 (54.3%) participants (**Table 5**). No deaths were reported.¹

Table 5. Summary of TEAEs – Safety Analysis Set⁸

	Placebo (N=94)	Trofinetide (N=93)
	n (%)	n (%)
Any TEAE	51 (54.3)	86 (92.5)
Any serious TEAE	3 (3.2)	3 (3.2)
Any related TEAE	20 (21.3)	78 (83.9)
Any related serious TEAE	1 (1.1)	2 (2.2)
Any TEAE leading to drug withdrawn	2 (2.1)	16 (17.2)*
Any severe TEAE	3 (3.2)	6 (6.5)
Any fatal TEAE	0	0

*During the NDA review, the FDA assigned 2 additional discontinuations due to TEAEs based on subject narratives, to be 18 (19%). This was reviewed and agreed upon by Acadia.

Abbreviations: NDA=New Drug Application; TEAE=treatment-emergent adverse event.

TEAEs $\geq 5\%$ in either treatment group are shown in **Table 6**. The most common TEAEs were diarrhea (80.6% with trofinetide vs. 19.1% with placebo), of which 97.3% in the trofinetide arm were characterized as mild-to-moderate, and vomiting (26.9% with trofinetide vs. 9.6% with placebo), of which 96% in the trofinetide arm were characterized as mild-to-moderate (**Table 6** and **Table 7**),¹ with the following definitions:³

- Mild: easily tolerated, causing minimal discomfort, and not interfering with normal everyday activities.
- Moderate: sufficiently discomforting to interfere with normal everyday activities.
- Severe: incapacitating and/or preventing normal everyday activities.

Table 6. TEAEs in $\geq 5\%$ in Either Treatment Group – Safety Analysis Set¹

Preferred Term	Placebo (N=94) n (%)	Trofinetide (N=93) n (%)
Diarrhea	18 (19.1)	75 (80.6)
Vomiting	9 (9.6)	25 (26.9)
Seizure	5 (5.3)	8 (8.6)
Pyrexia	4 (4.3)	8 (8.6)
Decreased appetite	2 (2.1)	5 (5.4)
Irritability	0	6 (6.5)

Abbreviation: TEAE=treatment-emergent adverse event.

Table 7. TEAEs in $\geq 5\%$ in Either Treatment Group by Severity – Safety Analysis Set¹

Preferred Term	Placebo (N=94) n (%)			Trofinetide (N=93) n (%)		
	Mild	Moderate	Severe	Mild	Moderate	Severe
Diarrhea	15 (16.0)	3 (3.2)	0	39 (41.9)	34 (36.6)	2 (2.2)
Vomiting	8 (8.5)	1 (1.1)	0	18 (19.4)	6 (6.5)	1 (1.1)
Seizure	3 (3.2)	2 (2.1)	0	3 (3.2)	5 (5.4)	0
Pyrexia	2 (2.1)	2 (2.1)	0	7 (7.5)	1 (1.1)	0
Decreased appetite	1 (1.1)	1 (1.1)	0	2 (2.2)	3 (3.2)	0
Irritability	0	0	0	3 (3.2)	2 (2.2)	1 (1.1)

Abbreviation: TEAE=treatment-emergent adverse event.

Serious TEAEs were observed in 3.2% of study participants in both the trofinetide and placebo groups.¹ Serious TEAEs were bacteremia/urinary tract infection/bronchiolitis (n=1), COVID-19 pneumonia (n=1), and seizure (n=1) in the participants treated with trofinetide, and respiratory distress (n=1), constipation (n=1), and pneumatosis intestinalis (n=1) in the participants treated with placebo.¹

Study treatment discontinuation rates related to TEAEs were 17.2% in the trofinetide group as compared to 2.1% in the placebo group (**Table 8**). In the trofinetide group, TEAEs leading to discontinuation of study drug were most commonly reported for diarrhea (12.9%), decreased appetite (3.2%), and lethargy and seizure (2.2% each).¹ All of the TEAEs leading to discontinuation of study drug were considered related to study drug, except for 1 case of arthralgia in the placebo group.⁸

Changes in laboratory tests, electrocardiograms and vital signs were generally small and similar in the treatment groups; none were considered clinically meaningful.¹ Small, transient changes in alanine aminotransferase values were reported in seven of 92 (7.6%) and three of 93 (3.2%) participants in the trofinetide and placebo groups, respectively. These changes were not associated with notable changes in other liver function tests, and no instances met Hy's law criteria.^{1,9}

Table 8. TEAEs Leading to Discontinuation of Study Drug – Safety Analysis Set^{1,8}

Preferred Term	Placebo (N=94)		Trofinetide (N=93)	
	Participants, n (%)	Events, n	Participants, n (%)	Events, n
Any TEAE leading to discontinuation of study drug	2 (2.1)	2	16 (17.2)*	23
Diarrhea	0	0	12 (12.9) [†]	12
Decreased appetite	0	0	3 (3.2)	3
Lethargy	0	0	2 (2.2)	2
Seizure	0	0	2 (2.2)	2
Frequent bowel movements	0	0	1 (1.1)	1
Gastroesophageal reflux disease	0	0	1 (1.1)	1
Vomiting	0	0	1 (1.1)	1
Weight decreased	0	0	1 (1.1)	1
Arthralgia	1 (1.1)	1	0	0
Pneumatosis intestinalis	1 (1.1)	1	0	0

*During the NDA review, the FDA assigned 2 additional discontinuations due to TEAEs based on subject narratives, to be 18 (19%). This was reviewed and agreed upon by Acadia.

[†]During the NDA review, the FDA assigned 2 additional discontinuations due to TEAEs of diarrhea based on subject narratives, to be 14 (15%). This was reviewed and agreed upon by Acadia.

Abbreviations: NDA=New Drug Application; TEAE=treatment-emergent adverse event.

References

1. Neul JL, Percy AK, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. *Nat Med*. 2023;29(6):1468-1475. [\[PubMed\]](#)
2. DAYBUE® (trofinetide) [package insert]. San Diego, CA. Acadia Pharmaceuticals Inc. [\[Link\]](#)
3. Acadia Pharmaceuticals Inc. Data on File. ACP-2566-003 Protocol. 2020.
4. National Institutes of Health. Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™). [\[Link\]](#).
5. Neul JL, Percy AK, Benke TA, et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. *Contemp Clin Trials*. 2022;114:106704. [\[PubMed\]](#)
6. Stallworth JL, Dy ME, Buchanan CB, et al. Hand stereotypies: Lessons from the Rett Syndrome Natural History Study. *Neurology*. 2019;92(22):e2594-e2603. [\[PubMed\]](#)
7. Neul JL, Percy AK, Benke TA, et al. Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome. *Pediatr Neurol*. 2024;152:63-72. [\[PubMed\]](#)
8. Acadia Pharmaceuticals Inc. Data on File. ACP-2566-003 Clinical Study Report. 2022.
9. Temple R. Hy's law: predicting serious hepatotoxicity. *Pharmacoepidemiol Drug Saf*. 2006;15(4):241-243. [\[PubMed\]](#)